{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:32:53Z","timestamp":1783632773733,"version":"3.55.0"},"reference-count":27,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Endocrine therapy is the mainstay treatment for hormone receptor-positive ductal carcinoma in situ. The aim of this study was to examine the long-term secondary malignancy risk of tamoxifen therapy. The data of patients diagnosed with breast cancer between January 2007 and December 2015 were retrieved from the database of the Health Insurance Review and Assessment Service of South Korea. The International Classification of Diseases, 10th revision, was used to track all-site cancers. Age at the time of surgery, chronic disease status, and type of surgery were considered covariates in the propensity score matching analysis. The median follow-up duration was 89 months. Forty-one patients in the tamoxifen group and nine in the control group developed endometrial cancer. The Cox regression hazard ratio model showed that tamoxifen therapy was the only significant predictor of the development of endometrial cancer (hazard ratio, 2.791; 95% confidence interval, 1.355\u20135.747; p = 0.0054). No other type of cancer was associated with long-term tamoxifen use. In consonance with the established knowledge, the real-world data in this study demonstrated that tamoxifen therapy is related to an increased incidence of endometrial cancer.<\/jats:p>","DOI":"10.3390\/diagnostics13040792","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T05:57:52Z","timestamp":1676872672000},"page":"792","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Risk of Secondary Cancer after Adjuvant Tamoxifen Treatment for Ductal Carcinoma In Situ: A Nationwide Cohort Study in South Korea"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1758-4439","authenticated-orcid":false,"given":"Dooreh","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Breast Surgery, Department of Surgery, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6721-399X","authenticated-orcid":false,"given":"Jooyoung","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9402-7591","authenticated-orcid":false,"given":"Jeong-Ho","family":"Seok","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6328-6948","authenticated-orcid":false,"given":"Hye Sun","family":"Lee","sequence":"additional","affiliation":[{"name":"Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9916-1917","authenticated-orcid":false,"given":"Soyoung","family":"Jeon","sequence":"additional","affiliation":[{"name":"Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7273-8886","authenticated-orcid":false,"given":"Chang Ik","family":"Yoon","sequence":"additional","affiliation":[{"name":"Division of Breast Surgery, Department of Surgery, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet"},{"key":"ref_2","first-page":"1652","article-title":"Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"97","author":"Fisher","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"827724","DOI":"10.3389\/fendo.2022.827724","article-title":"Estrogen Receptor Function: Impact on the Human Endometrium","volume":"13","author":"Yu","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_4","first-page":"855","article-title":"Tamoxifen treatment and gynecologic side effects: A review","volume":"97","author":"Mourits","year":"2001","journal-title":"Obstet. Gynecol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/86.20.1534","article-title":"Effects of tamoxifen on cardiovascular risk factors in postmeno-pausal women after 5 years of treatment","volume":"86","author":"Love","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_6","first-page":"375","article-title":"Tamoxifen treatment for the British Tamoxifen Second Cancer Study Group Tamoxifen Treatment for Breast Cancer and Risk of Endometrial Cancer: A Case-Control Study","volume":"97","author":"Swerdlow","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"ref_7","first-page":"1013","article-title":"Incidence of New Primary Cancers After Adjuvant Tamoxifen Therapy and Radiotherapy for Early Breast Cancer","volume":"83","author":"Andersson","year":"1991","journal-title":"Gynecol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(00)02677-5","article-title":"Risk and prognosis of endometrial cancer after tamoxifen for breast cancer","volume":"356","author":"Bergman","year":"2000","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00002018-200022010-00001","article-title":"Guidelines for monitoring patients taking tamoxifen treatment","volume":"22","author":"Neven","year":"2000","journal-title":"Drug Saf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cncr.31144","article-title":"Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients","volume":"124","author":"Rosenstock","year":"2017","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10549-016-4051-1","article-title":"Risk of acute myeloid leukemia and myelo-dysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511)","volume":"161","author":"Freedman","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1200\/JCO.1999.17.7.1988","article-title":"Epirubicin Plus Tamoxifen Versus Tamoxifen Alone in Node-Positive Postmenopausal Patients With Breast Cancer: A Randomized Trial of the International Collaborative Cancer Group","volume":"17","author":"Wils","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1002\/cam4.1698","article-title":"Radiation-associated sarcoma after breast cancer in a nationwide population: Increasing risk of angiosarcoma","volume":"7","author":"Salminen","year":"2018","journal-title":"Cancer Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"101857","DOI":"10.1016\/j.canep.2020.101857","article-title":"Incidence of radiation induced sarcoma attributable to radiotherapy in adults: A retrospective cohort study in the SEER cancer registries across 17 primary tumor sites","volume":"70","author":"Snow","year":"2020","journal-title":"Cancer Epidemiol."},{"key":"ref_15","unstructured":"World Health Organization (2004). International Statistical Classification of Diseases and Related health Problems: Tenth Revision, World Health Organization. [2nd ed.]."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1046\/j.1525-1497.2003.20724.x","article-title":"Meta-analysis of vascular and neoplastic events associated with tamoxifen","volume":"18","author":"Braithwaite","year":"2003","journal-title":"J. Gen. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","article-title":"Tamoxifen for prevention of breast cancer: Extended long-term follow-up of the IBIS-I breast cancer prevention trial","volume":"16","author":"Cuzick","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1200\/JCO.2003.03.114","article-title":"Acute myeloid leukemia and myelodysplastic syndrome after doxorubi-cin-cyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project Experience","volume":"21","author":"Smith","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1080\/0284186X.2016.1273547","article-title":"Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen","volume":"56","author":"Rosell","year":"2017","journal-title":"Acta Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/oxfordjournals.annonc.a010406","article-title":"Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan","volume":"11","author":"Matsuyama","year":"2000","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e2243951","DOI":"10.1001\/jamanetworkopen.2022.43951","article-title":"Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women With Breast Cancer","volume":"5","author":"Ryu","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"636378","DOI":"10.3389\/fonc.2021.636378","article-title":"Risk of Endometrial Cancer and Frequencies of Invasive Endometrial Procedures in Young Breast Cancer Survivors Treated With Tamoxifen: A Nationwide Study","volume":"11","author":"Choi","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.4103\/tcmj.tcmj_17_19","article-title":"Younger tamoxifen-treated breast cancer patients also had higher risk of endometrial cancer and the risk could be reduced by sequenced aromatase inhibitor use: A population-based study in Taiwan","volume":"32","author":"Chu","year":"2020","journal-title":"Tzu-Chi Med. J."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ignatov, A., and Ortmann, O. (2020). Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen. Cancers, 12.","DOI":"10.3390\/cancers12071766"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/2010105820948899","article-title":"Age-specific incidence rates of breast cancer among Japanese women increasing in a conspicuous bimodal distribution pattern","volume":"30","author":"Tokutake","year":"2020","journal-title":"Proc. Singap. Heal."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.7314\/APJCP.2012.13.12.6163","article-title":"A Comparison of the Cancer Incidence Rates between the National Cancer Registry and Insurance Claims Data in Korea","volume":"13","author":"Seo","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/4\/792\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:36:54Z","timestamp":1760121414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/4\/792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["diagnostics13040792"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics13040792","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]}}}